US Stocks Movement | Mesoblast rises nearly 7% as pivotal Phase 3 clinical trial for chronic low back pain makes progress

```htmlGlonhui July 15｜A certain exchange rose nearly 7% before the market, quoted at $17.89. The company announced today that in the pivotal phase III randomized controlled trial MSB-DR004 of rexlemestrocel-L for the treatment of chronic low back pain (CLBP) caused by degenerative disc disease, it has achieved the goal of at least 300 patients receiving treatment. The trial aims to validate the sustained pain relief effect observed with a single intradiscal injection of rexlemestrocel-L in the previous MSB-DR003 trial.```